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doi:10.1016/j.jtcvs.2007.12.0291110 The Journal of Thoracic and CarObjectives: We sought to investigate the release pattern of different cardiac bio-
markers (high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty
acid–binding protein, creatine kinase-MB, and myoglobin) and to establish the diag-
nostic discrimination limits of each marker protein to evaluate perioperative myocar-
dial injury in patients undergoing coronary artery bypass grafting with or without
cardiopulmonary bypass.
Methods: Fifty patients were randomly assigned to on-pump or off-pump coronary ar-
tery bypass grafting. All cardiac biomarkers were measured in serial venous blood sam-
ples drawn before heparinization in both groups and after aortic unclamping at 1, 2, 4, 8,
24, 48, and 72 hours in the on-pump group. In the off-pump group samples were taken
after the last distal anastomosis and at same time intervals as in the on-pump group.
Results: The total amount of heart-type fatty acid–binding protein, cardiac troponin I,
and high-sensitivity C-reactive protein released was significantly higher in the on-
pump group than in the off-pump group. Receiver operating characteristic curve
analysis of cardiac biomarkers indicated cardiac troponin I and heart-type fatty
acid–binding protein as the superior diagnostic discriminators of myocardial injury,
with an optimal cutoff value of greater than 0.92 ng/mL (area under the curve, 0.95
[95% CI, 0.88–1.00]; sensitivity, 92%; specificity, 92%; likelihood ratio [1],
11.50) and greater than 6.8 ng/mL (area under the curve, 0.94 [95% CI, 0.88–
1.00]; sensitivity, 88%; specificity, 88%; likelihood ratio [1], 7.33), respectively. Lo-
gistic regression analysis revealed that patients with increased cardiac troponin I
levels of greater than 0.92 ng/mL and heart-type fatty acid–binding protein levels
of greater than 6.8 ng/mL were at 132.25 (95% confidence interval, 17.14–
1020.49) times and 53.77 (95% confidence interval, 9.76–296.12) times higher risk
of myocardial injury after on-pump coronary artery bypass grafting.
Conclusions: Off-pump coronary artery bypass grafting provides better myocardial
protection than on-pump coronary artery bypass grafting. Cardiac troponin I and
heart-type fatty acid–binding protein, but not high-sensitivity C-reactive protein,
served as superior diagnostic discriminators of perioperative myocardial damage after
on-pump coronary artery bypass grafting.
C
oronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass
(CPB) is both safe and effective. Nevertheless, the use of CPB and cardiople-
gic arrest are associated with myocardial stunning and substantial morbidity.1
During the past decade, with the introduction of better stabilizing systems, such as thediovascular Surgery c May 2008
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octopus and the starfish, and other technical improvements,
there has been a revival of interest in performing CABG on
a beating heart. During this time, off-pump CABG has
been audited against on-pump CABG in many observational,
case-matched, and prospective randomized studies.1-3 The
published literature documents reduced blood loss and trans-
fusion requirements, reduction of postoperative morbidity,
organ dysfunction, and a more favorable outcome in selected
high-risk patients revascularized by using the off-pump tech-
nique.1-3
Myocardial ischemia during cardiac surgery results in
functional and structural changes and ultimately in release
of proteins from injured cardiac myocytes.1-3 The release pat-
tern of different proteins varies, as does their cardiospecific-
ity.4 Creatine kinase and its isoform, creatine kinase-MB
(CK-MB), have been the most frequently used tools in the di-
agnosis of myocardial ischemia.5 In recent years, structural
myofibrillar proteins, such as troponin T and troponin I,
along with their cardiospecific isoform, heart-type fatty
acid–binding protein (hFABP), high-sensitivity C-reactive
protein (hs-CRP), creatine kinase-MB (CK-MB), and myo-
globin, have entered the clinical field and have been used
in daily routine and in scientific clinical research. However,
the time delay between the operative damage and detection
of a measurable amount of protein in peripheral blood re-
mains a major concern, rendering difficulty in the rapid eval-
uation of the degree of myocardial injury. Second, markers
with improved sensitivity and specificity are required for ac-
curate and reliable information concerning myocardial bio-
chemistry.
The aims of this prospective study were (1) to investigate
the release of kinetics of different cardiac biochemical
markers (hs-CRP, cardiac troponin I [cTn-I], hFABP, CK-
MB, and myoglobin) and their relevance to myocardial injury
in patients undergoing beating- and arrested-heart revascular-
ization and (2) to measure the sensitivity, specificity, and the
likelihood ratio (1) of individual cardiac markers to establishThe Journal of Thorthe diagnostic discrimination limits of each marker protein to
evaluate perioperative myocardial injury.
Materials and Methods
Criteria for Patient Selection
This study conforms to the principles outlined in the declaration of
Helsinki. Fifty patients (41 male patients) scheduled to undergo first
elective CABG between June 2004 and March 2006 were enrolled
in this prospective randomized trial after obtaining the institutional
ethics committee’s approval and written informed consent from
each patient. All patients were eligible for both on-pump and off-
pump revascularization and were randomly distributed into one of
2 groups: (1) the on-pump group (n 5 25), in which the coronary
revascularization was done with the use of CPB and moderate hypo-
thermia, and (2) the off-pump group (n5 25), in which surgical in-
tervention was performed without the use of CPB. Their
demographic and clinical profiles are depicted in Table E1. There
was no significant difference between the 2 groups in age, sex,
weight, height, comorbidities, and medication. Cardiac catheteriza-
tion data were comparable in 2 population groups regarding the
number of diseased vessels. None of the patients received thrombo-
lytic agents.
Patients were excluded if any of the following criteria were pres-
ent: (1) emergency cardiac operations, (2) preoperative myocardial
infarction within the last 2 weeks or ongoing myocardial infarction,
(3) treatment with fibrinolytic agents within 48 hours before the op-
eration, (4) patients undergoing cardiac reoperations, (5) poor ven-
tricular function (ejection fraction,,0.30), (6) concomitant valvular
heart disease, (7) unstable angina, (8) renal disease, (9) chronic ob-
structive airway disease, (10) steroid therapy, (11) hepatic disease
(as indicated by aspartate aminotransferase or alanine aminotrans-
ferase levels of greater than 2 times the upper limit of normal or
by bilirubin levels of greater than 1.5 times the upper limit of nor-
mal), and (12) severe coagulation abnormalities.
Anesthetic Technique
All patients received a standardized anesthetic technique. Premedi-
cation included morphine (0.1 mg/kg) and promethazine (0.25 mg/
kg), both injected intramuscularly 1 hour before the operation. An-
esthesia was induced with midazolam (0.2 mg/kg), fentanyl (2–4
mg/kg), thiopentone sodium (2–5 mg/kg), and rocuronium (0.6–
0.9 mg/kg) and maintained with isoflurane (end-tidal concentration,
,1 minimum alveolar concentration), fentanyl (2 mg $ kg21 $ h21),
midazolam (0.04 mg $ kg21 $ h21), and pancuronium (0.8 mg $
kg21 $ h21). Perioperative antibiotic prophylaxis was provided
with 1 g of injection cefotaxime administered intravenously.
Heparin and Protamine Management
In the on-pump group heparin was administered at a dose of 3 mg/kg
to achieve a target activated clotting time (ACT) of 480 seconds or
greater before commencement of CPB. The ACT was monitored
during the bypass period (every 30 minutes), and an additional 0.5
mg/kg heparin was administered, if required. In the off-pump group
heparin (1.5 mg/kg) was administered before the start of the first
anastomosis or before the division of the left internal thoracic artery.
The target ACT in this group was 250 to 300 seconds. Protamine
sulfate was used to reverse the effect of heparin at a dose ratio of
1.5:1 at the end of the operation.acic and Cardiovascular Surgery c Volume 135, Number 5 1111
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On-pump group. All patients in this group underwent revascu-
larization during CPB by using aortoatrial cannulation and moderate
systemic hypothermia. The extracorporeal device consisted of
a roller pump, a reservoir, and a membrane oxygenator. The prime
of the circuit consisted of 1500 mL of Ringer’s lactate containing 0.5
g/kg of mannitol and 5000 IU of heparin. The pump flows were ad-
justed to maintain a cardiac index of greater than 2.4 L $ min21 $
m22. Aprotinin, 3-aminocaproic acid, or tanexamic acid were not
administered to any patient in the on-pump group. Myocardial pro-
tection was achieved by means of anterograde intermittent adminis-
tration of a cold blood St Thomas–based cardioplegic solution both
through the aortic root and through the graft after completion of each
distal anastomosis. Ischemic preconditioning or retrograde cardio-
plegia was not used on any patient.
After distal anastomosis and once the left internal thoracic artery
was unclamped, warm reperfusion composed exclusively of 37C
oxygenated blood was administered through a multiperfusion cath-
eter with a constant flow rate of between 200 and 500 mL/min to
minimize myocardial ischemia.
Off-pump group. In the off-pump group colloids were adminis-
tered, and position changes and gravity support (Trendelenburg and
right and left table rotation) were used to stabilize patients’ hemo-
dynamics and to maintain a controlled systolic arterial pressure be-
tween 120 and 140 mm Hg to optimize coronary perfusion. The
distal anastomoses were performed first. Single aortic side clamp-
ing was performed to minimize the risk of aortic trauma during
multiple proximal anastomoses. The systolic blood pressure was
decreased to about 80 to 90 mm Hg for application of the side
clamp and to minimize the risk of aortic injury and atheroemboli-
zation. This level of systemic arterial pressure was maintained dur-
ing the time that the side-biting clamp was placed on the aorta for
the proximal anastomosis. Lesions of the left anterior descending
coronary artery were bypassed with a left internal thoracic artery
pedicle graft, where feasible. Target artery immobilization and re-
gional myocardial control was achieved through a commercially
available Octopus III stabilizer-suction system (Octopus Tissue
Stabilizer; Medtronic, Inc, Eden Prairie, Minn). Intracoronary
shunts were used if there was (1) excessive bleeding at the site
of arteriotomy obscuring adequate visualization despite using a mis-
ter blower, (2) electrocardiographic evidence of new-onset regional
ischemia, or (3) ventricular dysfunction to provide distal flow until
completion of the anastomosis.
Biochemical Analysis
Blood samples were collected from each patient after sternotomy
and before systemic heparinization, 1 hour after declamping (or af-
ter completion of last distal anastomosis in off-pump group), and
then at 2, 4, 8, 24, 48, and 72 hours in both groups. Samples
were immediately cooled to 4C and centrifuged at 3000 rpm
for 10 minutes at 4C. Serum was stored at 270C until assay. Se-
rum levels of hFABP were measured by means of enzyme-linked
immunosorbent assay (Hycult Biotechnology, Uden, The Nether-
lands), and levels of CK-MB were measured by using the photo-
metric method (Diasys Diagnostic System GmbH, Holzheim,
Germany). cTn-I and myoglobin levels were measured by using
immunometric technology (Diagnostic Products Corp, Los An-
geles, Calif). Ultrasensitive C-reactive protein levels were mea-1112 The Journal of Thoracic and Cardiovascular Surgery c Msured by using diagnostic kits from Spinreact, SA, Citra Santa
Coloma (Sant Esteve Debas [GI], Spain).
Clinical Variables
In addition to biochemical measurements, we recorded patients’
needs for inotropic agents, duration of ventilatory support, and in-
tensive care unit (ICU) stay. A patient’s inotropic requirement
was classified as none, mild (dopamine, #5 mg $ kg21 $ min21),
or moderate (dopamine, .5 mg $ kg21 $ min21; dobutamine, .5
mg $ kg21 $ min21; or adrenaline, ,0.1 mg $ kg21 $ min21).
Twelve-lead electrocardiographic recordings were performed
preoperatively, at 2 hours postoperatively, and then daily for at least
the first 3 postoperative days. All patients had continuous electrocar-
diographic monitoring until they were discharged from the ICU.
A single cardiologist, who was blinded to the study, performed
transthoracic 2-dimensional echocardiography in all patients to
evaluate left ventricular function at 8 hours postoperatively and
again before discharge. Left ventricular function was defined as
moderate (ejection fraction, 0.30–0.50) or good (ejection fraction,
.0.50).
Definitions
Perioperative myocardial injury. Perioperative myocardial
infarction represents the most severe complication at the end of an
adverse cascade, usually initiated by episodes of prolonged suben-
docardial ischemia, which might occur as a reversible or irreversible
event and is no longer viewed as a binary event. It is now held that
there is a spectrum of myocardial injury characterized by increasing
release of cardiac biomarkers to a full-blown picture of myocardial
infarction.1-4,6,7 The reported incidence of perioperative myocardial
injury after CABG has varied considerably, ranging between 5%
and 20%, partly as a result of the use of different definitions and di-
agnostic criteria.1-4 The pathogenesis of perioperative myocardial
injury after CABG is based on a variety of graft-related and
non–graft-related mechanisms. The graft-related reasons are graft
occlusion, graft kinking or overstretching, subtotal anastomotic
stenosis, or graft spasm. Non–graft-related causes include
direct myocardial trauma by means of surgical manipulation, inad-
equate cardioplegic perfusion and myocardial protection, incom-
plete revascularization, and distal coronary microembolization
caused by surgical manipulation.1-14 The gap between reversible
myocardial ischemia and definite death of myocardial cells of a ma-
jor area might be linked by appropriate assessment of minor myocar-
dial cellular injury, which could help to prevent myocardial
infarction.1-14
For uniformity with other studies, perioperative myocardial in-
jury was considered to be present in the presence of one of the fol-
lowing criteria: (1) appearance of a new and persistent Q-wave with
a duration of greater than 40 ms in at least 2 adjacent leads; (2) dis-
appearance of an R-wave or 25% reduction of R-waves in 2 leads;
(3) appearance of ST-segment deviations at the J-point in 2 or
more contiguous leads with cutoff points of greater than 0.2 mV
in leads V1, V2, or V3 and greater than 0.1 mV in other leads or
T-wave abnormalities in 2 or more continuous leads; (4) appearance
of a new-onset left bundle branch block; (5) new and persistent wall-
motion abnormalities on transesophageal echocardiography; and (6)
requirement of inotropic support to maintain stable hemodynamics
as stated in the absence of mechanical external compression.ay 2008
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put syndrome after CABG was diagnosed if the patient required ino-
tropic support in the ICU, required intra-aortic balloon assistance
postoperatively, or both.1-4,15 It was diagnosed if the patient re-
quired inotropic support (dopamine, 4–10 mg $ kg21 $ min21; do-
butamine, 5–10 mg $ kg21 $ min21; epinephrine, 0.01–0.1 mg $
kg21 $ min21; milrinone, 50 mg/kg intravenous bolus followed by
0.375-0.75 mg $ kg21 $ min21), either isolated or in combination,
in the operating room or in the ICU to maintain stable hemodynam-
ics in the absence of mechanical external compression after correc-
tion of all electrolytes or blood gas abnormalities and after adjusting
the preload to its optimal value.1-4,15
Low output syndrome was also diagnosed if there was an in-
creasing requirement of the abovementioned inotropes along with
afterload reduction with sodium nitroprusside. Patients who re-
ceived less than 4 mg $ kg21 $ min21 of dopamine to increase renal
perfusion were not considered to have low output syndrome.1-4,15
Generally under the definition of low output syndrome after
CABG, an integration of relevant clinical, laboratory, and bedside
echocardiographic criteria were used. The criteria for diagnosis
were cold extremities, absent pedal pulses, decreased toe tempera-
ture, reduced systolic pressure (,90 mm Hg), decreased cardiac
output (,2.2 L $ min21 $ m22) or at least 30 minutes in the operat-
ing room or ICU, impaired renal function and oliguria (,1.0 mL $
kg21 $ h21), metabolic acidosis, increased serum lactate levels ($2
mmol/L for greater than 2 hours), low mixed venous oxygen satura-
tion (#50%), and blunt sensorium.
Statistical Analysis
Statistical analysis was carried out with STATA 9.0 software (Col-
lege Station, Tex). Continuous and interval-related data were pre-
sented as means 6 standard deviation and medians (ranges),
whereas categorical variables were presented as frequency distribu-
tions and percentages. At each time point, the difference in the me-
dians of all cardiac biomarker values between the on-pump and off-
pump procedures were compared by using the Wilcoxon rank sum
test because the data were nonnormal and mean value was not the
right measure. Within the group, the difference in the medians
was compared by using Friedman 2-way analysis of variance.
A receiver operating characteristic (ROC) curve analysis was
used to identify the discrimination limits for each of the cardiac bio-
markers at each time point separately in predicting myocardial in-
jury, taking the on-pump CABG group as the riskier group. The
area under the ROC curve (95% confidence interval [CI]), sensitiv-
ity, specificity, and the likelihood ratio were calculated to analyze
the diagnostic value of each markers.16 Logistic regression was car-
ried out to quantify the risk of myocardial injury at a specified time
point after the operation in patients undergoing on-pump CABG by
using each of the cardiac biomarkers.
Although ROC curves are usually used to evaluate and compare
an operator or diagnostic test with a gold standard and to explore the
tradeoffs between sensitivity and specificity for a test, the areas un-
der the ROC curves are independent of both the cutoff point criteria
(predicted probabilities) and the prevalence of outcomes.16 In this
study ROC analysis was performed after calculating the sensitivity
and specificity for all the values (cutoff point) of a particular cardiac
biomarker. In this process of calculating sensitivity and specificity,
neither of these was affected by extreme values or wide variationsThe Journal of Thor(Table E5). Therefore we used these curves to provide an additional
diagnostic tool to determine the discrimination limit for each of the
cardiac biomarkers after on-pump CABG.
Results
There was no operative or hospital mortality for either the on-
pump or off-pump groups. There were no conversions from
the off-pump to on-pump groups.
In the on-pump group CPB time was 106.8 6 30.6 min-
utes, and aortic crossclamp time was 52.8 6 17.5 minutes.
The number of distal anastomoses performed in the 2 groups
was marginally different and did not reach statistical signifi-
cance (3.26 0.62 vs 3.16 0.60, P5 .56). Despite following
a standardized protocol for the length of ventilation and insti-
tution of inotropes in the setting of low output syndrome, sig-
nificant differences were observed between the on-pump and
off-pump CABG groups in duration of mechanical ventilation
(18.60 6 3.62 vs 12.80 6 2.42 hours, P , .0001) and ICU
stay (41.286 0.62 vs 35.806 1.8 hours,P, .001; Table E2).
Four (16%) patients in the on-pump group and 18 (72%)
in the off-pump group required no inotropic drug support.
Four (16%) patients in the on-pump group required moderate
inotropic support because of low output syndrome, whereas
no patient required such support in the off-pump group (Ta-
ble E3). There was no perioperative myocardial infarction in
either group, as defined by electrocardiographic criteria or in-
hospital death. The postoperative course was uneventful in
all patients. There was transient moderate impairment of
left ventricular ejection fraction ranging between 0.30 and
0.50 at 8 hours in all but 1 patient who underwent on-pump
CABG (96% on-pump vs 68% off-pump, P 5 .023). How-
ever, there was no noticeable difference in this regard at dis-
charge (Table E3).
Time Course of Median Concentration of Biomarkers
The median values of each marker protein increased from
a baseline concentration preoperatively to a postoperative
peak, indicating myocardial damage of a certain degree in
all cases. The total amount of biomarkers released in both
groups has not been considered for comparative evaluation
of myocardial injury because an initially increased value
can take a few days to resolve and would be counted or added
to the total amount as high on multiple occasions.
For each sample drawn, hs-CRP concentrations were sig-
nificantly higher in the on-pump group than in the off-pump
group at 4 hours (P 5 .04), and 8 hours (P 5 .009) only
(Table E4, A, and Figure 1).
For each sample drawn, cTn-I concentrations were signif-
icantly higher in the on-pump group than in the off-pump
group at 1 hour (P , .0001), 2 hours (P , .0001), 4 hours
(P , .0001), 8 hours (P , .0001), and 24 hours (P 5 .04).
However, cTn-I concentrations were comparable at 48 and
72 hours (Table E4, B, and Figure 2).acic and Cardiovascular Surgery c Volume 135, Number 5 1113
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reactive protein (hs-CRP) concentrations broken
down by surgical procedure (on-pump vs off-
pump) at baseline (0), 1 hour, 2 hours, 4 hours, 8
hours, 24 hours, 48 hours, and 72 hours, respec-
tively. Dots represent the outliers that were out-
side the calculated range, possibly because of
biologic variability. The 2 measurements differed
significantly (P 5 .04). The hs-CRP concentration
was significantly higher in the on-pump group
than in the off-pump group at 4 hours (P 5 .04)
and 8 hours (P 5 .009) only.For each sample drawn, hFABP concentrations were sig-
nificantly higher at 1 hour (P , .0001), 2 hours (P 5 .001),
4 hours (P 5 .0002), 8 hours (P 5 .0008), 24 hours (P 5
.0002), 48 hours (P5 .0004), and 72 hours (P, .0001; Table
E4, C, and Figure 3).
The degree of CK-MB increase was significantly higher in
the on-pump group at 1 hour (P5 .001), 2 hours (P5 .005),
and 4 hours (P 5 .0008) only (Table E4, D, and Figure 4).
For each sample drawn, myoglobin concentration was sig-
nificantly higher only at 1 hour (P5 .001) and 2 hours (P5
.04) after surgical intervention in the on-pump group (Table
E4, E, and Figure 5).1114 The Journal of Thoracic and Cardiovascular Surgery c MDiagnostic Performance of hsCRP, cTn-I, hFABP,
CK-MB, and Myoglobin
To determine the optimal cutoff values and test characteris-
tics of the abovementioned cardiac markers at every postop-
erative time point in patients undergoing on-pump CABG,
ROC analysis revealed the following.
cTn-I was the best diagnostic discriminator of myocar-
dial injury, with an optimal cutoff value of greater than
0.92 ng/mL at 1 hour after aortic declamping (area under
the curve [AUC], 0.95 [95% CI, 0.88–1.0]; sensitivity,
92%, specificity, 92%; likelihood ratio [1], 11.50; Table
E6 and Figure 6).Figure 2. Release kinetics of cardiac troponin I
(cTn-I) concentrations broken down by surgical
procedure (on-pump vs off-pump) at baseline (0),
1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours,
and 72 hours, respectively. Dots represent the
outliers that were outside the calculated range,
possibly because of biologic variability. The 2
measurements differed significantly (P 5 .001).
The cTn-I concentration was significantly higher
in the on-pump group than in the off-pump group
at 1 hour (P < .0001), 2 hours (P < .0001), 4 hours
(P < .0001), 8 hours (P < .0001), and 24 hours
(P 5 .04).ay 2008
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acid-binding-protein (h-FABP) concentrations
broken down by surgical procedure (on-pump vs
off-pump) at baseline (0), 1 hour, 2 hours, 4 hours,
8 hours, 24 hours, 48 hours, and 72 hours, respec-
tively. Dots represent the outliers that were out-
side the calculated range, possibly because of
biologic variability. The 2 measurements differed
significantly (P < .0001). The hFABP concentra-
tion was significantly higher in the on-pump
group than in the off-pump group at 1 hour (P <
.0001), 2 hours (P 5 .001), 4 hours (P 5 .0002), 8
hours (P 5 .0008), 24 hours (P 5 .0002), 48 hours
(P 5 .0004), and 72 hours (P < .0001).A
CDhFABP was the second-best diagnostic discriminator of
perioperative myocardial injury, with an optimal cutoff value
of greater than 6.8 ng/mL at 1 hour after aortic declamping
(AUC, 0.94 [95% CI, 0.88–1.00]; sensitivity, 88%, specific-
ity, 88%; likelihood ratio [1], 7.33; Table E6 and Figure 6).
hs-CRP increase did not significantly separate patients un-
dergoing postoperative CABG (on-pump) without myocar-
dial injury. The optimally chosen cutoff values determined
for hs-CRP, CK-MB, and myoglobin are presented in Table
E6. In an attempt to predict the risk of myocardial injury afterThe Journal of Thoraon-pump CABG by means of logistic regression analysis us-
ing each cardiac biomarkers revealed the following. Patients
with increased hFABP levels of greater than 6.8 ng/mL,
cTn-I levels of greater than 0.92 ng/mL, CK-MB levels of
greater than 48.9 log units/mL, and myoglobin levels of
greater than 176 mg/mL were at 53.77 (95% CI, 9.76–
296.12) times, 132.25 (95% CI, 17.14–1020.49) times, 6.61
(95% CI, 1.92–22.72) times, and 10.02 (95% CI, 2.74–
36.72) times higher risk of myocardial injury after on-pump
CABG. Increased hs-CRP levels were nonpredictors ofFigure 4. Release kinetics of creatine kinase-MB
(CKMB) concentrations broken down by surgical
procedure (on-pump vs off-pump) at baseline (0),
1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours,
and 72 hours, respectively. Dots represent the out-
liers that were outside the calculated range, pos-
sibly because of biologic variability. The degree
of CK-MB increase was significantly higher in
the on-pump group at 1 hour (P 5 .001), 2 hours
(P 5 .005), and 4 hours (P 5 .0008) only.cic and Cardiovascular Surgery c Volume 135, Number 5 1115
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trations broken down by surgical procedure (on-
pump vs off-pump) at baseline (0), 1 hour, 2 hours,
4 hours, 8 hours, 24 hours, 48 hours, and 72 hours,
respectively.Dots represent the outliers that were
outside the calculated range, possibly because of
biologic variability. The degree of myoglobin in-
crease was significantly higher in the on-pump
group at 1 hour (P 5 .001) and 2 hours (P 5 .04)
only.myocardial injury in patients undergoing CABG with CPB
(Table E6 and Figure 6).
Discussion
As far as we could establish, there are limited studies in the
English-language literature addressing specifically the com-
parative release pattern and optimal cutoff values of different
cardiac biomarkers, namely hs-CRP, cTn-I, hFABP, CK-
MB, and myoglobin, for evaluating the degree of periopera-
tive myocardial injury after surgical revascularization with or
without CPB.1-5,8-14 The diagnostic discrimination limits of
the cardiac biomarkers and the ability to predict the risk of
myocardial injury after on-pump CABG by using the degree1116 The Journal of Thoracic and Cardiovascular Surgery c Mof increase of cardiac biomarker levels also have not been
established.1-5,8-14
The major finding in this investigation was consistently
higher increases of hs-CRP, cTn-I, hFABP, CK-MB, and
myoglobin levels in the on-pump group than in the off-
pump group. The second important finding was identification
of the best diagnostic discriminator of myocardial injury by
using ROC curve analysis of all the cardiac biomarkers. The
third important finding was the ability to predict the risk of
myocardial injury after on-pump CABG by using the degree
of increase of cardiac biomarkers, namely hFABP, cTn-I, CK-
MB, and myoglobin. The increase of hs-CRP levels was a non-
predictor of myocardial injury after on-pump CABG.Figure 6. The receiver operating characteristic
(ROC) curve of the study group to compare the
tradeoffs between the true-positive rate and the
false-positive rate of increase of all cardiac
biomarker levels to identify all the diagnostic
discrimination limits for each markers (high-sen-
sitivity C-reactive protein, heart-type fatty acid–
binding protein, cardiac troponin I, creatine ki-
nase-MB, and myoglobin). Cardiac troponin I
and heart-type fatty acid–binding protein were
superior diagnostic discriminators of myocardial
injury after on-pump coronary artery bypass graft-
ing.ay 2008
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Application for Detection of Myocardial Injury
Cardiospecific marker proteins are intracellular molecules
soluble in cytoplasm or bound to subcellular structures that
are released to the extracellular space after damage of the
myocardial cell membrane. Plasma levels of specific marker
proteins follow a typical pattern. Small water-soluble mole-
cules are more rapidly washed out and detectable in the serum
than proteins with a larger molecular mass, mainly because of
the permeability of the endothelial layer.4,5,9,14,17
An ideal marker of myocardial injury would (1) be found
in high concentrations in myocardium; (2) not be found in
other tissues, even in trace amounts or under pathologic con-
ditions; (3) be released rapidly and completely after myocar-
dial injury; (4) be released in direct proportion to the extent of
myocardial injury; and (5) persist in plasma for several hours
to provide a convenient diagnostic time window but not so
long that recurrent injury would not be identified. Thus
markers with improved sensitivity and specificity are re-
quired for accurate and reliable information concerning myo-
cardial biochemistry.4,5,9,14
hFABP is a water-soluble, small, intracellular protein con-
sisting of 132 amino acid residues and weighing 14,500 d. Its
physiologic role is the transport of hydrophobic long-chain
fatty acids from the cell membrane to mitochondria to enter
the citric acid cycle. After membrane damage, it is released
to the extracellular space and, because of its small size,
immediately enters the blood compartment.19,17-19
The published literature on the use of hFABP in cardiac
surgical patients is limited,10,17-19 although it has been re-
ported to be a highly sensitive marker of myocardial injury
and perioperative myocardial ischemia. Petzold and co-
workers10 investigated the release pattern of hFABP, CK-
MB, and troponin I during conventional CABG at intervals
of 5 and 60 minutes after declamping and 1, 2, and 10 days
thereafter. They concluded that hFABP is a rapid marker of
myocardial damage and peaks earlier than CK-MB or tropo-
nin I. Hasegawa and colleagues18 evaluated hFABP and con-
cluded that it might be a rapid and potentially useful
prognostic indicator of myocardial damage and clinical out-
come in pediatric cardiac surgery.
CRP is a 135,000-d nonimmunoglobulin protein having 5
identical subunits.4,9,14,20,21 Assay for C-reactive protein has
a sensitivity of about 5 mg/L. By using this assay, its level
could be detected only when it is significantly increased. Re-
cently available high-sensitivity assay of C-reactive protein
(hs-CRP) using labeling of anti-CRP antibodies with another
enzyme (enzyme-linked immunosorbent assay) or a fluores-
cent compound and attaching the antibody, either monoclo-
nal or polyclonal, to polystyrene beads 1 to 6 allows
measurement of a C-reactive protein concentration as low
as 0.15 mg/L.20,21 To our knowledge, no studies have used
hs-CRP to compare the degree of myocardial injury after
revascularization with and without using CPB.The Journal of ThorMyoglobin is a low-molecular-weight heme protein
(17,800 d) that is abundant in cardiac and skeletal muscles
but not in smooth muscle. Thus it is a sensitive but not specific
marker of acute myocardial infarction, requiring the exclusion
of skeletal muscle injury.4,5,22 Myoglobin is rapidly released
from the necrotic myocardium, with subsequent rapid renal
clearance. Because of rapid kinetics, myoglobin can define
the timing of myocardial events if frequent samples are ob-
tained.4,5,22 Myoglobin is often detectable 2 hours after coro-
nary occlusion, with peak levels occurring at 3 to 15 hours. A
pattern of discontinuous release of myoglobin consisting of
multiple peaks or the ‘‘staccato phenomenon’’ has been
reported to occur in patients who have had acute myocardial
infarction caused by coronary occlusion and reperfusion.23
For nearly 3 decades, MB isoenzymes of creatine kinase
have been the molecular marker of choice for evaluation of
patients with suspected acute myocardial infarction. CK iso-
enzymes are dimers composed of 39,000- to 42,000-d sub-
units synthesized in the cytosol of myocytes. CK
isoenzymes are composed of two M-subunits (MMCK),
two B-subunits (BBCK), or one M and one B subunit
(MBCK). BBCK is the most abundant in the brain, MMCK
in striated muscle, and MBCK in the heart.4,5,9 The disadvan-
tage of CK-MB as a cytosolic marker of perioperative myo-
cardial cellular injury compared with troponins is not only its
lower sensitivity and specificity but also the short diagnostic
window of approximately 24 hours.24
Troponins are regulatory proteins (I, C, or T) located in the
striated muscle. They regulate actinomyosin interactions.
cTn-I and cardiac troponin T have small cytosol distribution
and are tightly complexed to the contractile apparatus. These
are more specific markers of myocardial injury and have been
shown to predict the risk of mortality and cardiac events in
patients with unstable angina to estimate infarct size after re-
perfusion and lower release pattern in patients with off-pump
CABG compared with on-pump CABG.4,5,8,9,11-14,24,25
Diagnostic Performance of Different Cardiac
Biomarkers: Clinical Implications and
Recommendations
Perioperative myocardial infarction after CABG remains a se-
rious complication with a high risk of early and late mortality,
as well as poor long-term outcome.1-4,6,7 The reported inci-
dence varies between 5% and 20% in different publica-
tions.1-4,6,7 However, its prevalence depends on the tests
and diagnostic criteria used. Electrocardiographic criteria re-
main uncertain and lack diagnostic accuracy in both the early
and late postoperative periods. The primary goal of postoper-
ative biochemical monitoring of cardiac patients is to estab-
lish appropriate markers to detect early minor cardiac
cellular injury to inhibit postoperative myocardial infarction
and to exclude the existence of cardiac complications. There-
fore diagnosis depends on assessment of plasma levels of car-
diospecific marker proteins.1-14acic and Cardiovascular Surgery c Volume 135, Number 5 1117
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termine the release kinetics of the cardiac biomarkers, (hs-
CRP, cTn-I, hFABP, CK-MB, and myoglobin) in on-pump
and off-pump revascularization. With regard to preoperative
and operative data, randomization created 2 equivalent
groups for all the variables (Table E1).
Because the decision regarding the vessels to be grafted
was made before randomization and in no case was the
planned program aborted, the number of bypasses per patient
was marginally different in both groups, including the num-
ber of arterial grafts (3.26 0.62 vs 3.16 0.60, P5 .56). We
concur with the observations of other investigators on the re-
duced requirement of inotropic support in patients undergo-
ing revascularization without CPB compared with the on-
pump group (P , .0001, Table E3).1-3
In this study there were consistently higher increases of all
cardiac biomarkers in patients undergoing arrested-heart re-
vascularization than in the beating-heart group. This indicates
more myocardial injury despite optimal cardioprotection in
the on-pump group compared with that in the off-pump group.
A comparatively higher release of hFABP, cTn-I, and CK-
MB in patients undergoing on-pump CABG is probably be-
cause on-pump CABG results in global ischemia whereas
off-pump CABG leads to localized ischemia.
Although the cutoff values of cardiac markers have been
reported elaborately for patients presenting with chest
pain,5,11,12,26 these values are not well established for assess-
ment of myocardial injury in patients undergoing surgical re-
vascularization with or without CPB. Based on the data in the
present study, we found optimal cutoff values and test char-
acteristics of all available cardiac biomarkers using ROC
curves in patients undergoing CABG with CPB.
ROC analysis of cardiac biomarkers indicated cTn-I as the
best diagnostic discriminator of myocardial injury, with an
optimal cutoff value of greater than 0.92 ng/mL (AUC,
0.95 [95% CI, 0.88–1.0]; sensitivity, 92%; specificity,
92%; likelihood ratio [1], 11.50; Table E6 and Figure 6).
hFABP was the second-best diagnostic discriminator of peri-
operative myocardial injury, with an optimal cutoff value of
greater than 6.8 ng/mL (AUC, 0.94 [95% CI, 0.88–1.00];
sensitivity, 88%; specificity, 88%; likelihood ratio [1],
7.33; Table E6 and Figure 6). hs-CRP increase did not signif-
icantly separate patients undergoing postoperative CABG
(on-pump) with or without myocardial injury.
Thus in patients undergoing CABG with the potential for
concomitant myocardial and skeletal muscle injury, the high
cardiospecificity of hFABP and cTn-I could make these
markers reliable tools in the diagnosis of perioperative myo-
cardial injury and in comparison of different cardioplegia
techniques.
ROC curve analysis of cardiac biomarkers indicated cTn-I
and hFABP as the superior diagnostic discriminators of myo-
cardial injury, with optimal cutoff values of greater than 0.92
ng/mL at 1 hour after aortic declamping (AUC, 0.95 [95% CI,1118 The Journal of Thoracic and Cardiovascular Surgery c M0.88–1.00]; sensitivity, 92%; specificity, 92%; likelihood ra-
tio [1], 11.50) and greater than 6.8 ng/mL at 1 hour after aor-
tic declamping (AUC, 0.94 [95% CI, 0.88–1.00]; sensitivity,
88%; specificity, 88%; likelihood ratio [1], 7.33). Logistic
regression revealed patients with increased cTn-I values of
greater than 0.92 ng/mL and hFABP levels of greater than
6.8 ng/mL were at 132.25 (95% CI, 17.14–1020.49) times
and 53.77 (95% CI, 9.76–296.12) times higher risk of myo-
cardial injury after on-pump CABG. Increased hs-CRP levels
were nonpredictors of myocardial injury in patients undergo-
ing CABG with CPB.
While analyzing the release kinetics of different marker
proteins, we found that hFABP concentrations were signifi-
cantly higher in every sample drawn from patients undergoing
arrested-heart revascularization, whereas cTn-I concentra-
tions were significantly higher only until the 8-hour mark.
At 24, 48, and 72 hours, cTn-I concentrations were compara-
ble in our 2 groups. Moreover, hFABP concentrations peaked
earlier in both groups compared with cTn-I concentrations. It
is noteworthy that the hs-CRP increase did not significantly
separate patients undergoing postoperative CABG (on-
pump) with or without myocardial injury.
The above observations have important implications in
the management of patients undergoing CABG with or with-
out CPB in the early postoperative period. Although most pa-
tients have an uneventful postoperative period after CABG,
irrespective of technique, and few have had clinically signif-
icant myocardial infarction, intensive care specialists are of-
ten confronted with a large group of patients whose clinical
situations are borderline (nonspecific electrocardiographic
changes and mild hypotension with or without inotropes).
Release of hFABP could help identify those patients at an
early stage who, because of cardiac damage, could benefit
from prolonged monitoring in an ICU. Thus hFABP peaks
earlier than cTn-I or hs-CRP/CK-MB. With the introduction
of rapid assays, perioperative myocardial damage can be
evaluated in the operating theater.
Study Limitations
Our study had its limitations in the evaluation of left ventric-
ular function in the postoperative period. Transthoracic echo-
cardiographic analysis might not be a sufficient tool for
evaluation of left ventricular function because of a poor win-
dow in the immediate postoperative period. Radionuclide
studies or magnetic resonance imaging (MRI) for assessment
of left ventricular function would have consolidated our find-
ings, and better distinction between the 2 groups could have
been established.
Second, it is unknown whether this reduction in release
of myocardial enzymes in the off-pump group is associated
with reduced perioperative myocardial stunning (revers-
ible) or necrosis (irreversible) because enzyme release
might be partly due to increased turnover of cytoplasmic
pools. A comparative quantification of myonecrosis inay 2008
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CPB using cine-MRI and contrast-enhanced MRI would
have assessed the functional significance of these biochem-
ical markers.
Third, when assessing the utility of a biochemical test, the
ability to compare it with an established gold standard is par-
amount. Unfortunately, there is no easily applicable gold
standard for the diagnosis of postoperative myocardial infarc-
tion. Like us, most authors used electrocardiographic criteria
of newly developed Q-waves, left bundle branch block, ST-T
changes, and/or echocardiographically detected and newly
developed wall-motion abnormalities. Of note, electrocardio-
graphic or echocardiographic changes would not allow the
diagnosis of smaller or nontransmural infarcts to be tested.
Conclusions
We conclude that measurable transient subclinical cardiac
damage exists during surgical revascularization, and this
damage is greater with on-pump revascularization, despite
advances in myocardial preservation and CPB conduction.
hFABP peaks earlier than cTn-I or CK-MB, and there was
a trend toward hFABP and cTn-I being superior diagnostic dis-
criminators of perioperative myocardial damage. Serial deter-
mination of serum hFABP and cTn-I values immediately
after reperfusion in the early postoperative period are useful
in rapid detection of perioperative myocardial injury. hs-CRP
is an unreliable diagnostic discriminator of perioperative myo-
cardial injury. The high cardiospecificity of hFABP and cTn-I
could make these reliable diagnostic tools in the diagnosis of
perioperative myocardial injury, the comparison of different
myocardial preservation strategies, and further decisions about
diagnostic and therapeutic options in these patients.
The authors are grateful to Mr. Shankar Sharma for preparation
of the manuscript.
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CDTABLE E1. Baseline characteristics of the study group (n 5 50)
Variables On-pump CABG Off-pump CABG P value
No. of patients (%) 25 (50%) 25 (50%) –
Age (y), mean 6 SD (range) 60.2 6 6.8 (50–74) 58.8 6 7.8 (40–71) .5
Male population (n [%]) 21 (84%) 20 (80%) 1.00
Weight (kg), mean 6 SD (range) 65 6 5.8 (46–84) 61.8 6 6.2 (47–83) .06
Height (cm), mean 6 SD (range) 164.2 6 4.8 (155–172) 163.9 6 4.6 (154–168) .82
Preoperative left ventricular ejection
fraction, mean 6 SD (range)
0.52 6 0.60 (0.40–0.60) 0.54 6 0.64 (0.35–0.68) .9
No. of diseased vessels, mean 6 SD (range) 2.8 6 0.6 (2–3) 2.8 6 0.4 (1–3) 1.00
Diabetes mellitus (n [%]) 7 (28%) 8 (32%) .76
Hypertension (n [%]) 14 (56%) 15 (60%) .77
Preoperative myocardial infarction (n [%]) 10 (40%) 11 (44%) .77
Smoking (n [%]) 3 (12%) 9 (36%) 1.00
Medications
b-adrenergic blockers (n [%]) 23 (92%) 22 (88%) 1.00
Angiotensin-converting enzyme inhibitors (n [%]) 11 (44%) 12 (48%) .77
Nitrates (n [%]) 24 (96%) 25 (100%) 1.00
Boldface indicates statistical significance, CABG, Coronary artery bypass grafting; SD, standard deviation.1119.e1 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Chowdhury et al Surgery for Acquired Cardiovascular DiseaseTABLE E2. Perioperative variables of the study group
Variables On-pump CABG Off-pump CABG P value
Total no. of distal anastomoses 3.2 6 0.62 3.1 6 0.60 .56
Bypass conduit
LITA (n) 19 22 .46
Radial artery (n) 4 5 1.00
Perioperative MI 0 0 –
ST-T wave changes 0 0 –
Requirement for IABP 0 0 –
Duration of ventilation (h) 18.60 6 3.62 12.80 6 2.42 <.001
ICU length of stay (h) 41.28 6 0.62 35.80 6 1.8 <.001
Boldface indicates statistical significance. CABG, Coronary artery bypass grafting; LITA, left internal thoracic artery; MI, myocardial infarction; IABP, Intra-
aortic balloon-pump, ICU, intensive care unit.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1119.e2
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CDTABLE E3. Inotropic drug requirement and postoperative left ventricular function of the study group
Variables On-pump CABG, no. (%) Off-pump CABG, no. (%) P value
Inotropic drug requirement
None (NTG or SNP) 4 (16%) 18 (72%)
Mild (dopamine ,5 mg $ kg21 $ min21) 17 (68%) 7 (28%) <.0001
Moderate (dopamine/dobutamine .5 mg $ kg21 $ min21
or adrenaline ,0.1 mg $ kg21 $ min21)
4 (16%) 0
LV function at 8 h
Moderate (EF 5 0.30–0.50) 24 (96%) 17 (68%) .023
Good (EF .0.50) 1 (4%) 8 (32%)
LV function before discharge
Moderate (EF 5 0.30–0.50) 14 (56%) 12 (48%) .57
Good (EF .0.50) 11 (44%) 13 (52%)
Boldface indicates statistical significance. CABG, Coronary artery bypass grafting; NTG, nitroglycerin; SNP, sodium nitroprusside; EF, ejection fraction.1119.e3 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Chowdhury et al Surgery for Acquired Cardiovascular DiseaseTABLE E4A. Perioperative values of cardiac biomarkers after coronary artery bypass grafting performed with 2 different
techniques at different time intervals: High-sensitivity C-reactive protein (mg/L)
Time intervals (h)
On-pump (group I), mean 6 SD
(range, median)
Off-pump (group II), mean 6 SD
(range, median) P value
Baseline 3.78 6 2.74 (0.3–10.8, 3.1) 4.2 6 2.95 (0.6–10.2, 2.7) .76
1 3.26 6 2.98 (0.7–12.4, 2.5) 3.72 6 3.90 (0.7–15.5, 2.4) .78
2 2.65 6 2.73 (0.5–10.4, 1.5) 2.57 6 2.80 (0.2–12.4, 1.8) .80
4 4.36 6 2.87 (1.3–12.3, 3.6) 2.9 6 2.25 (0.4–10.4, 2.4) .04
8 6.6 6 2.9 (2.1–12.8, 6) 4.6 6 3.36 (1.2–10.9, 2.6) .009
24 1.9 6 0.68 (1–3, 1.9) 1.86 6 0.57 (1–2.6, 2) .41
48 2.31 6 0.92 (1.1–4.5, 2.2) 1.96 6 0.68 (0.2–2.7, 2.2) .26
72 2.18 6 0.89 (0.9–4.4, 2.2) 2.04 6 0.68 (0.2–3.1, 2.2) .67
Boldface indicates statistical significance. SD, Standard deviation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1119.e4
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CDTABLE E4B. Perioperative values of cardiac biomarkers after coronary artery bypass grafting performed with 2 different
techniques at different time intervals: Cardiac troponin I (ng/mL)
Time intervals (h)
On-pump (group I), mean 6 SD
(range, median)
Off-pump (group II), mean 6 SD
(range, median) P value
Baseline 0.29 6 0.48 (0–1.5, 0.2) 0.42 6 1.03 (0.2–5.4, 0.2) .06
1 3.02 6 3.13 (0.5–14, 2) 0.49 6 1.02 (0.2–5.3, 0.2) <.0001
2 5.03 6 4.79 (0–17, 2.5) 0.65 6 1.23 (0.2–5.6, 0.2) <.0001
4 8.9 6 7.5 (1.2–28, 5.5) 1.05 6 1.86 (0.2–7.5, 0.36) <.0001
8 8.4 6 7.52 (1.3–27.5, 6) 7.63 6 18.26 (0.2–58, 0.68) <.0001
24 3.45 6 3.87 (0–18, 2.1) 13.75 6 29.03 (0.2–94.8, 0.98) .04
48 1.61 6 1.41 (0–6, 1) 0.2 6 84.1 (8.68–19.62, 0.83) .91
72 0.83 6 0.86 (0–3.5, 0.69) 6.24 6 13.79 (0.2–56.4, 0.4) .47
Boldface indicates statistical significance. SD, Standard deviation.1119.e5 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Chowdhury et al Surgery for Acquired Cardiovascular DiseaseTABLE E4C. Perioperative values of cardiac biomarkers after coronary artery bypass grafting performed with 2 different
techniques at different time intervals: Heart-type fatty acid–binding protein (ng/mL)
Time intervals (h)
On-pump (group I), mean 6 SD
(range, median)
Off-pump (group II), mean 6 SD
(range, median) P value
Baseline 2.0 6 2.21 (0.2–9, 1.25) 1.41 6 1.86 (0.12–6.5, 0.5) .06
1 43.52 6 36.76 (1.2–115, 31) 3.80 6 9.29 (0.2–47, 1) <.0001
2 30.78 6 24.32 (2–82.5, 23.5) 4.52 6 10.91 (0.2–55, 1) .001
4 14.72 6 15.14 (1–60, 7) 6.2 6 12.06 (0.13–45, 0.6) .0002
8 10.14 6 10.4 (0.31–41, 7.5) 6.5 6 13.61 (0.12–45.5, 0.8) .0008
24 7.94 6 9.20 (0.31–43, 4.5) 2.51 6 3.64 (0.2–12, 0.8) .0002
48 5.87 6 6.67 (0.25–26, 4) 5.54 6 21.83 (0–110, 0.5) .0004
72 3.49 6 3.53 (0.1–2.5, 1.6) 0.47 6 1.17 (0–5.5, 0) <.0001
Boldface indicates statistical significance. SD, Standard deviation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1119.e6
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CDTABLE E4D. Perioperative values of cardiac biomarkers after coronary artery bypass grafting performed with 2 different
techniques at different time intervals: Creatine kinase-MB (log units/mL)
Time intervals (h)
On-pump (group I), mean 6 SD
(range, median)
Off-pump (group II), mean 6 SD
(range, median) P value
Baseline 15.83 6 16.31 (1.3–70, 9) 22.07 6 14.96 (38–57, 21.3) .08
1 63.01 6 57.40 (2.4–272, 45.5) 29.99 6 35.27 (1.5–161, 2) .001
2 83.46 6 70.61 (0.6–301) 10.62 6 19.72 (3.4–74.5, 25) .005
4 100.13 6 81.69 (2.9–353, 73) 36.04 6 31.35 (1.2–131, 36.9) .0008
8 107.27 6 90.39 (0–372, 86) 60.47 6 70.51 (1.4–272, 384) .12
24 100.17 6 106.70 (1.6–373, 54.1) 110.78 6 130.36 (2.8–475, 56.7) .86
48 88.38 6 81.82 (6.9–314, 48.9) 96.75 6 93.73 (3.2–320, 478) .89
72 72.75 6 72.95 (3.3–340, 40) 75.20 6 86.91 (1.7–367, 35.1) .81
Boldface indicates statistical significance. SD, Standard deviation.1119.e7 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Chowdhury et al Surgery for Acquired Cardiovascular DiseaseTABLE E4E. Perioperative values of cardiac biomarkers after coronary artery bypass grafting performed with 2 different
techniques at different time intervals: Myoglobin (mg/mL)
Time intervals (h)
On-pump (group I), mean 6 SD
(range, median)
Off-pump (group II), mean 6 SD
(range, median) P value
Baseline 96.95 6 70.08 (19.1–289, 71.3) 90.18 6 75.96 (1.1–311, 67.9) .42
1 399.66 6 262.22 (67–1000, 416) 135.94 6 70.77 (3.2–249, 147) .001
2 349.48 6 234.71 (131–957, 293) 191.40 6 90.69 (64.4–434, 154) .04
4 186.32 6 87.96 (60.8–407, 176) 166.58 6 101.48 (59.8–477, 137) .23
8 152.14 6 79.03 (1.3–362, 134) 196.03 6 115.18 (66.6–528, 159) .25
24 272.51 6 245.46 (2.6–1000, 207) 258.98 6 191.29 (32–1000, 238) .71
48 183.15 6 138.81 (30–611, 152) 203.85 6 203.87 (30–1000, 133) .69
72 119.21 6 72.62 (26–244, 123) 156.24 6 204.06 (26.7–480, 85.8) .91
Boldface indicates statistical significance. SD, Standard deviation.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1119.e8
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Surgery for Acquired Cardiovascular Disease Chowdhury et al
A
CDTABLE E5. Area under the ROC curves and optimal cutoff values for each cardiac marker at every postoperative time point in
patients undergoing CABG in the study group (on-pump) and the likelihood ratio
Marker
Time (h) after
arrival at ICU
Cutoff
value
Area under ROC
curve (95% CI)
Sensitivity
(%)
Specificity
(%)
Likelihood
ratio (1)
High- sensitivity C-reactive protein (mg/L) 1 $2.5 0.52 (0.36–0.68) 56 56 1.27
2 $1.6 0.52 (0.35–0.68) 48 48 0.92
4 $2.9 0.66 (0.51–0.82) 64 64 1.77
8 $5.6 0.71 (0.56–0.86) 64 64 1.77
24 $2.0 0.56 (0.40–0.73) 48 48 0.92
48 $2.3 0.59 (0.42–0.75) 48 56 1.09
72 $2.2 0.53 (0.36–0.70) 52 48 1.00
Cardiac troponin I (ng/mL) 1 $0.92 0.95 (0.88–1.00) 92 92 11.50
2 $1.2 0.91 (0.81–1.00) 84 88 7.00
4 $2.1 0.94 (0.87–1.00) 88 88 7.33
8 $2.9 0.84 (0.70–0.97) 84 84 5.25
24 $1.7 0.66 (0.49–0.83) 68 68 2.12
48 $0.9 0.50 (0.33–0.68) 76 52 1.58
72 $1.4 0.44 (0.27–0.61) 52 56 1.18
Heart-type fatty acid–binding protein (ng/mL) 1 $6.8 0.94 (0.88–1.00) 88 88 7.33
2 $6.5 0.91 (0.83–0.99) 80 84 5.00
4 $5.0 0.81 (0.68–0.94) 76 80 3.80
8 $4.5 0.77 (0.63–0.91) 68 72 2.42
24 $3.0 0.80 (0.67–0.92) 76 76 3.16
48 $1.4 0.79 (0.66–0.92) 72 72 2.57
72 $0.6 0.82 (0.71–0.94) 80 80 4.0
Creatine kinase MB (log units/mL) 1 $30.0 0.75 (0.62–0.89) 68 68 2.12
2 $38.9 0.76 (0.62–0.90) 76 76 3.16
4 $42.9 0.77 (0.64–0.90) 72 72 2.57
8 $48.03 0.70 (0.55–0.86) 76 76 3.16
24 $56.7 0.48 (0.32–0.64) 48 48 0.9
48 $70.7 0.48 (0.32–0.65) 52 52 1.08
72 $40.6 0.52 (0.35–0.68) 48 52 1.00
Myoglobin (mg/mL) 1 $176 0.82 (0.69–0.94) 76 76 3.16
2 $196 0.72 (0.58–0.87) 68 68 2.12
4 $173 0.59 (0.43–0.76) 56 56 1.27
8 $157 0.40 (0.24–0.56) 44 44 0.78
24 $244 0.47 (0.30–0.63) 44 44 0.78
48 $166 0.49 (0.32–0.66) 50 52 1.04
72 $123 0.50 (0.34–0.67) 56 56 1.27
Boldface indicates statistical significance. ROC, Receiver operating characteristic; CABG, coronary artery bypass grafting; ICU, intensive care unit; CI, con-
fidence interval.1119.e9 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Chowdhury et al Surgery for Acquired Cardiovascular DiseaseTABLE E6. Risk of myocardial injury after on-pump CABG surgery by means of logistic regression by using each of the
cardiac biomarkers
Cardiac biomarkers Time (h)
Cutoff
value
On-pump,
no. (%)
Off-pump,
no. (%) OR (95% CI) P value
High- sensitivity C-reactive protein (mg/L) 8 $5.6 95 79 3.16 (0.99–10.03) .05
#5.6 80 96
Cardiac troponin I (ng/mL) 1 $0.92 129 46 132.25 (17.14–1020.49) <.0001
#0.92 40 135
Heart-type fatty acid–binding protein (ng/mL) 1 $6.8 138 40 53.77 (9.76–296.12) <.0001
#6.8 37 138
Creatine kinase-MB (log units/mL) 4 $42.9 112 63 6.61 (1.92–22.72) .003
#42.9 65 110
Myoglobin (mg/mL) 1 $176 87 70 10.02 (2.74–36.72) <.001
#176 87 105
Boldface indicates statistical significance. CABG, Coronary artery bypass grafting; OR, odds ratio; CI, confidence interval.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1119.e10
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